19 completed, 6 terminated, 2 active not recruiting, 2 recruiting. 8 Not applicable, 8 Phase 2, 7 Phase 1, 5 Phase 4, 2 Phase 3.
Follow sandostatin: new trials by email Literature Review of sandostatin trials Research Report on sandostatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas Sacituzumab Govitecan, EKG, Brain MRI - Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2025-06-09 | 2026-01-21 |
| Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtients Somatostatin analog - Gastroenteropancreatic Neuroendocrine Tumor | Phase 4 | Recruiting | University Hospital, Antwerp | 270 | 2023-06-28 | 2024-06-14 |
| Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors Incomplete Freund's Adjuvant, Octreotide Acetate, Sargramostim - Lung Atypical Carcinoid Tumor, Lung Typical Carcinoid Tumor | Phase 1 | Completed | Roswell Park Cancer Institute | 19 | 2019-06-17 | 2026-02-06 |
| Terlipressin on Effect of Renal Function in Cirrhotic Patients With Acute Gastrointestinal Hemorrhage Terlipressin, Somatostatin, Octreotide - Variceal Hemorrhage, Cirrhosis, Liver | Completed | General Hospital of Shenyang Military Region | 1682 | 2019-03-01 | 2019-07-05 | |
| A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors Ga-68-DOTA-TOC, Siemens PET/MR scanner, Standard Siemens Software - Small Bowel Carcinoid Tumor | Phase 1 | Withdrawn | Massachusetts General Hospital | 2018-11-01 | 2019-06-21 | |
| A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers ONO-5788, ONO-5788 Placebo, Octreotide - Acromegaly | Phase 1 | Terminated | Ono Pharmaceutical Co., Ltd. | 76 | 2018-06-07 | 2019-06-05 |
| The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research Transnasal butterfly surgery, sandostatin, radiotherapy - Acromegaly | Recruiting | Ginkgo Leaf Center for Rare Disorders | 1965 | 2017-12-15 | 2022-03-16 | |
| Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber Octreotide LAR - Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage | Phase 2 | Unknown | Radboud University Medical Center | 15 | 2016-10-01 | 2018-04-20 |
| Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients Octreotide - Octreotide, Sputum | Phase 2 | Completed | Danbury Hospital | 5 | 2016-09-01 | 2020-10-08 |
| Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation Sandostatin - Neuroendocrine Tumors, Carcinoid Syndrome | Phase 4 | Terminated | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 10 | 2016-02-02 | 2019-10-25 |
| Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy Blumgart Anastomosis, Cattell-Warren Anastomosis, Octreotide - Pancreatic Cancer | Phase 3 | Completed | University of Liverpool | 295 | 2015-04-23 | 2025-03-13 |
| The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery Octreotide, Placebo - Esophageal Neoplasms, Stomach Neoplasms | Not applicable | Completed | St. James's Hospital, Ireland | 40 | 2015-03-01 | 2023-11-27 |
| Effects of Glucagon Administration on Energy Expenditure Glucagon, Octreotide, Placebo - Hyperglucagonemia, Obesity | Phase 1 | Completed | AdventHealth Translational Research Institute | 6 | 2014-09-01 | 2018-04-26 |
| Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy Octreotide, Placebo - Periampullary Carcinoma Resectable | Not applicable | Completed | Mansoura University | 104 | 2014-05-01 | 2017-08-22 |
| Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer Octreotide, Placebo - Esophageal Neoplasms, Stomach Neoplasms | Not applicable | Completed | St. James's Hospital, Ireland | 20 | 2014-01-01 | 2023-11-27 |
| Acromegaly Combination Treatment Study Pegvisomant, Octreotide LAR, Lanreotide - Acromegaly | Not applicable | Terminated | Cedars-Sinai Medical Center | 76 | 2012-03-29 | 2023-01-04 |
| Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Bevacizumab, Everolimus, Octreotide Acetate - Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 150 | 2010-10-15 | 2022-08-04 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Cixutumumab, Everolimus, Laboratory Biomarker Analysis - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-10-01 | 2016-07-15 |
| Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle Pioglitazone, Insulin, Octreotide - Obesity, Sarcopenia | Not applicable | Completed | University of Nottingham | 26 | 2009-10-01 | 2014-12-02 |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2008-11-07 | 2023-07-05 |
Showing 20 of 32. Sign in to see all of them.
Acromegaly (4) · Neuroendocrine Tumors (4) · Weight Loss (4) · Obesity (3) · Adenoma, Islet Cell (2) · Esophageal Neoplasms (2) · Fibrosis (2) · Glucagonoma (2) · Insulinoma (2) · Malnutrition (2) · Pancreatic Neoplasms (2) · Prader-Willi Syndrome (2) · Somatostatinoma (2) · Stomach Neoplasms (2) · Vipoma (2)
National Cancer Institute (NCI) (4) · St. James's Hospital, Ireland (2) · AdventHealth Translational Research Institute (1) · Aga Khan University (1) · Cedars-Sinai Medical Center (1) · Changhai Hospital (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Danbury Hospital (1) · Duke University (1) · Eastern Cooperative Oncology Group (1) · General Hospital of Shenyang Military Region (1) · Ginkgo Leaf Center for Rare Disorders (1) · Korea University (1) · Mansoura University (1) · Massachusetts General Hospital (1)
United States (17) · China (2) · Ireland (2) · Netherlands (2) · Sweden (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Egypt (1) · Norway (1) · Pakistan (1) · South Korea (1)
John V Reynolds, MCh, FRCS (2) · Abhijith Hegde, MD (1) · Andrea M Haqq, MD (1) · Ayman El Nakeeb, MD (1) · Bert H. O'Neil, MD (1) · Charles Ryan, MD (1) · Christian Meyer, MD (1) · Christopher Halloran (1) · David Spiegel (1) · Italo Biaggioni, MD (1) · Ivan Borbath, Prof (1) · James C Yao (1) · James Yao (1) · Jasmeet Kaur, MD (1) · Jonathan Q Purnell, M.D. (1)
PMID 10662747, PMID 10973392, PMID 11904109, PMID 11927799, PMID 12119802, PMID 12832331, PMID 15066944, PMID 15710782, PMID 15738343, PMID 15911704, PMID 17515447, PMID 17515448, PMID 18492760, PMID 19687359, PMID 20837887, PMID 20884247, PMID 21521254, PMID 22311903, PMID 23494109, PMID 23557411, PMID 23842691, PMID 24002370, PMID 24092547, PMID 24227635, PMID 24495468, PMID 24606242, PMID 24721800, PMID 24866574, PMID 25900182, PMID 25937757, PMID 26583672, PMID 27271310, PMID 28384065, PMID 29853660, PMID 30722001, PMID 32673517, PMID 32754748, PMID 32860184, PMID 39727053, PMID 40615151, PMID 7809832, PMID 9727818
P30CA016672 (1), U01CA062461 (1), U10CA023318 (1), U10CA031946 (1), U10CA032102 (1), U10CA180821 (1), U10CA180888 (1), UL1TR000445 (1)